The DOI matches its Crossref record.
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses
Open accessAbstract
Abstract Background Actinic keratoses (AKs) are epidermal skin lesions with the potential to develop into invasive squamous cell carcinoma (SCC). Treatment at an early stage may prevent development of SCC. Current treatment options are highly destructive and associated with significant side‐effects. Early studies with topical diclofenac were encouraging and led to its evaluation for the treatment of actininic keratosis. Previous studies have demonstrated that 3% diclofenac in 2.5% hyaluronan gel is effective and well tolerated in the treatment of AK. The present study was designed to further explore the therapeutic potential of this gel. Methods This randomized, double‐blind, placebo‐controlled trial involved outpatients with a diagnosis of five or more AK lesions contained in one to three 5 cm 2 blocks. Patients received either active treatment (3% diclofenac gel in 2.5% hyaluronan gel) or inactive gel vehicle (hyaluronan) as placebo (0.5 g b.i.d. in each 5 cm 2 treatment area for 90 days). Assessments included the Target Lesion Number Score (TLNS), Cumulative Lesion Number Score (CLNS), and Global Improvement Indices rated separately by both the investigator (IGII) and patient (PGII). Results Results obtained from 96 patients at follow up (30 days after end of treatment) indicated that a significantly higher proportion of patients who received active treatment had a TLNS = 0 compared to the placebo group (50% vs. 20%; P < 0.001). There was also a significant difference between the two groups in CLNS, with 47% of patients in the active treatment group having a CLNS = 0 compared with only 19% in the placebo group (P < 0.001). The proportion of patients with an IGII score of 4 (completely improved) at follow‐up was 47% in the active treatment group compared with only 19% in the placebo group (P < 0.001); for PGII these values were 41% vs. 17%, P < 0.001. Both treatments were well tolerated, with most adverse events related to the skin. Conclusions Topical 3% diclofenac in 2.5% hyaluronan gel was effective and well tolerated for the treatment of AK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The magic glue hyaluronan and its eraser hyaluronidase: A biological overview
Girish, K. S., & Kemparaju, K. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.02.037 · Cited by 674
Radiation dermatitis: Clinical presentation, pathophysiology, and treatment 2006
Hymes, S. R., Strom, E. A., & Fife, C. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.08.054 · Cited by 645
Ingenol Mebutate Gel for Actinic Keratosis
Lebwohl, M., Swanson, N., Anderson, L. L., Melgaard, A., Xu, Z., & Berman, B. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111170 · Cited by 471
Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin
Brown, M., & Jones, S. (2005) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2004.01180.x · Cited by 373
Hyaluronan: Pharmaceutical Characterization and Drug Delivery
Liao, Y.-H., Jones, S. A., Forbes, B., Martin, G. P., & Brown, M. B. (2005) · Drug Delivery · doi:10.1080/10717540590952555 · Cited by 342
Metadata
- Authors
- Wolf, J. E., Taylor, J. R., Tschen, E., & Kang, S.
- Venue
- International Journal of Dermatology
- Publisher
- Wiley
- Published
- 2001-11
- Volume
- 40
- Issue
- 11
- Pages
- 709-713
- ISSN
- 0011-9059 (ISSN-L)
- 1365-4632
- OpenAlex
- W2168408099
- Cited by
- 238
- References
- 0
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. https://app.cochat.ai/papers/10.1046/j.1365-4362.2001.01324.x
- The paper
- Wolf, J. E., Taylor, J. R., Tschen, E., & Kang, S. (2001). Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. International Journal of Dermatology. https://doi.org/10.1046/j.1365-4362.2001.01324.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.